RLYB — Rallybio Corp

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1739410 ·
Last close
$15.29
Market Cap
$82.32M
52W High
$17.57
52W Low
$3.67
ADV30
29,254
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -3,423,000 -2,725,000 95,579,000 90,693,000 3,283,000
Jun 2026 0 — -5,653,000 43,665,000 98,063,000 92,849,000 3,567,000
Mar 2026 212,000 — -8,733,000 -8,278,000 54,472,000 41,299,000 4,195,000
Dec 2025 222,000 — -6,412,000 -5,852,000 62,261,000 31,374,000 4,305,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$30,986,000
Investing CF
$27,325,000
Financing CF
$260,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$8.43
As of
2026-11-01

Balance + Analyst (yfinance extras)

Retained Earnings
$-269,336,000
Inventory
—
Receivables
—
ST Investments
$0
EBIT TTM
$-24,221,000
Pretax Income TTM
$28,214,000
Interest Exp TTM
—
Analysts
—

Yahoo Snapshot (yfinance, live)

Total Revenue
$434,000
EBITDA
$-21,913,000
Free Cash Flow
$-9,390,625
Enterprise Value
$-7,026,619
Total Cash
$90,693,000
Total Debt
$0
Shares Out
5,383,937
Trailing EPS
$4.61
Book Value
$17.31
ROE
34.5%
ROA
-16.8%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 858,000 -33,064,000 -8,978,000 62,261,000 4,305,000 57,956,000 -29,813,000
Dec 2024 636,000 -60,496,000 -57,775,000 68,108,000 6,454,000 61,654,000 -49,282,000
Dec 2023 0 -78,932,000 -74,564,000 115,620,000 9,436,000 106,184,000 -60,265,000
Dec 2022 0 -67,884,000 -66,654,000 180,435,000 11,118,000 169,317,000 -57,284,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$646,000
NetIncome TTM
$45,551,000
OpCashFlow TTM
—
Assets (Latest)
$98,063,000
Forward EPS
$-5.40

Peers — same industry

TickerNameMarket CapLastDaily %
TLSA Tiziana Life Sciences Ltd $82.46M $0.65 —
ZOMDF Zomedica Corp. $83.30M $0.09 —
RACC Research Alliance Corp III $78.68M $10.12 —
DERM Journey Medical Corp $86.70M $3.90 —
RVRC Revium Rx. $86.84M $1.43 —

News headlines (Yahoo Finance, 1h cache)

Rallybio Announces Reverse Stock Split of Common Stock in Connection with the Proposed Merger with Avenzo
2026-11-10 22:15 · Yahoo
Rallybio Stockholders Approve Avenzo Merger, Name Change and Reverse Split
2026-11-04 21:14 · Yahoo
RLYB Stock Hits 2-Year Highs After Unveiling Merger With Avenzo – How Much Of The New Company Will Rallybio Shareholders Own?
2026-06-01 16:26 · Yahoo
Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement
2026-06-01 12:00 · Yahoo
RallyBio tries again for reverse merger, this time with Avenzo
2026-06-01 15:03 · Yahoo
Correction to Press Release Announcing Reverse Stock Split of Rallybio Common Stock in Connection with the Proposed Merger with Avenzo
2026-11-11 13:15 · Yahoo
VERAXA Biotech Expands R&D Hub in Heidelberg as Programs Advance Towards Clinical Development
2026-06-24 18:15 · Yahoo
Prolium Bioscience Sclerosis, Lupus Treatment Studies Advancing
2026-06-22 15:40 · Yahoo
Stock Splits Matter: Notable Splits in 2025 and What’s Happening in 2026
2026-02-04 15:05 · Yahoo
Rallybio to acquire Candid Therapeutics
2026-03-03 12:29 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.